Company Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001.
NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Hyung-Heon Kim |
Contact Details
Address: 545 Concord Avenue, Suite 210 Cambridge, Massachusetts 02138 United States | |
| Phone | (857) 702-9600 |
| Website | neurobopharma.com |
Stock Details
| Ticker Symbol | NRBO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638287 |
| CUSIP Number | 64132R107 |
| ISIN Number | US64132R4048 |
| Employer ID | 47-2389984 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hyung-Heon Kim | Chief Executive Officer, President, Principal Executive and Director |
| Marshall H. Woodworth | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Mi-Kyung Kim | Chief Scientific Officer |
| Robert Homolka | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | EFFECT | Notice of Effectiveness |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 8-K | Current Report |